Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

G1 Therapeutics Inc

GTHX
Current price
7.15 USD 0 USD (0.00%)
Last closed 7.15 USD
ISIN US3621LQ1099
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 377 221 120 USD
Yield for 12 month +511.11 %
1Y
3Y
5Y
10Y
15Y
GTHX
21.11.2021 - 28.11.2021

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. Address: 700 Park Offices Drive, Research Triangle Park, NC, United States, 27709

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.15 USD

P/E ratio

Dividend Yield

Current Year

+82 511 000 USD

Last Year

+51 301 000 USD

Current Quarter

+16 546 000 USD

Last Quarter

+14 476 000 USD

Current Year

+75 316 000 USD

Last Year

+47 553 000 USD

Current Quarter

+15 813 000 USD

Last Quarter

+13 397 000 USD

Key Figures GTHX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -37 388 000 USD
Operating Margin TTM -21.37 %
PE Ratio
Return On Assets TTM -19.2 %
PEG Ratio
Return On Equity TTM -109.01 %
Wall Street Target Price 7.15 USD
Revenue TTM 58 195 000 USD
Book Value 0.47 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -61 %
Dividend Yield
Gross Profit TTM 47 553 000 USD
Earnings per share -0.86 USD
Diluted Eps TTM -0.86 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -76.93 %

Dividend Analytics GTHX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History GTHX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation GTHX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 6.2627
Price Sales TTM 6.482
Enterprise Value EBITDA -6.1587
Price Book MRQ 15.3392

Financials GTHX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GTHX

For 52 weeks

1.09 USD 7.19 USD
50 Day MA 5.84 USD
Shares Short Prior Month 4 389 180
200 Day MA 4.1 USD
Short Ratio 1.01
Shares Short 3 409 663
Short Percent 6.52 %